The therapeutic potential of targeting the K_ir1.1 (renal outer medullary K⁺) channel

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Huang J, Gretz N, Weinfurter S. Filtration markers and determination methods for the assessment of kidney function. Eur. J. Pharmacol. 790, 92–98 (2016).
  Medline CASGoogle Scholar
• 2 Hebert SC. Roles of Na-K-2Cl and Na-Cl cotransporters and ROMK potassium channels in urinary concentrating mechanism. Am. J. Physiol. 275(3 Pt 2), F325–F327 (1998). • Function of Kir1.1 in the thick assending limb of Henle.
  Medline CASGoogle Scholar
• 3 Nichols CG, Lopatin AN. Inward rectifier potassium channels. Annu. Rev. Physiol. 59, 171–191 (1997).
  Medline CASGoogle Scholar
• 4 Xu JZ, Hall AE, Peterson LN, Bienkowski MJ, Eessalu TE, Hebert SC. Localization of the ROMK protein on apical membranes of rat kidney nephron segments. Am. J. Physiol. 273(5 Pt 2), F739–F748 (1997).
  Medline CASGoogle Scholar
• 5 Antes LM, Kujubu DA, Fernandez PC. Hypokalemia and the pathology of ion transport molecules. Semin. Nephrol. 18(1), 31–45 (1998). • Explanation of renal transport functions associated with hypokalemia.
  Medline CASGoogle Scholar
• 6 Fodstad H, Gonzalez-Rodriguez E, Bron S et al. Effects of mineralocorticoid and K⁺ concentration on K⁺ secretion and ROMK channel expression in a mouse cortical collecting duct cell line. Am. J. Physiol. Renal Physiol. 296(5), F966–F975 (2009).
  Medline CASGoogle Scholar
• 7 Palmer LG, Frindt G. Amiloride-sensitive Na channels from the apical membrane of the rat cortical collecting tubule. Proc. Natl Acad. Sci. USA 83(8), 2767–2770 (1986).
  Medline CASGoogle Scholar
• 8 Rossier BC, Canessa CM, Schild L, Horisberger JD. Epithelial sodium channels. Curr. Opin. Nephrol. Hypertens. 3(5), 487–496 (1994).
  Medline CASGoogle Scholar
• 9 Frindt G, Palmer LG. Low-conductance K channels in apical membrane of rat cortical collecting tubule. Am. J. Physiol. 256(1 Pt 2), F143–F151 (1989).
  Medline CASGoogle Scholar
• 10 Frindt G, Palmer LG. Ca-activated K channels in apical membrane of mammalian CCT, and their role in K secretion. Am. J. Physiol. 252(3 Pt 2), F458–F467 (1987).
  Medline CASGoogle Scholar
• 11 Gray DA, Frindt G, Palmer LG. Quantification of K⁺ secretion through apical low-conductance K channels in the CCD. Am. J. Physiol. Renal Physiol. 289(1), F117–F126 (2005). • Function of Kir1.1 in the cortical collecting duct.
  Medline CASGoogle Scholar
• 12 Woda CB, Bragin A, Kleyman TR, Satlin LM. Flow-dependent K⁺ secretion in the cortical collecting duct is mediated by a maxi-K channel. Am. J. Physiol. Renal. Physiol. 280(5), F786–F793 (2001).
  Medline CASGoogle Scholar
• 13 Bailey MA, Cantone A, Yan Q et al. Maxi-K channels contribute to urinary potassium excretion in the ROMK-deficient mouse model of Type II Bartter's syndrome and in adaptation to a high-K diet. Kidney Int. 70(1), 51–59 (2006).
  Medline CASGoogle Scholar
• 14 Cornelius RJ, Wang B, Wang-France J, Sansom SC. Maintaining K balance on the low Na, high K diet. Am. J. Physiol. Renal Physiol. 310, F581–F595 (2016). •• Molecular mechanisms involved in the maintenance of potassium homeostasis based on dietary potassium intake.
  Medline CASGoogle Scholar
• 15 Vucic E, Alfadda T, Macgregor GG, Dong K, Wang T, Geibel JP. Kir1.1 (ROMK) and Kv7.1 (KCNQ1/KvLQT1) are essential for normal gastric acid secretion: importance of functional Kir1.1. Pflugers Arch. 467(7), 1457–1468 (2015). • Report of a physiological role of Kir1.1 outside of the kidney.
  Medline CASGoogle Scholar
• 16 Spector DA, Yang Q, Klopouh L et al. The ROMK potassium channel is present in mammalian urinary tract epithelia and muscle. Am. J. Physiol. Renal Physiol. 295(6), F1658–F1665 (2008).
  Medline CASGoogle Scholar
• 17 Dvoryanchikov G, Sinclair MS, Perea-Martinez I, Wang T, Chaudhari N. Inward rectifier channel, ROMK, is localized to the apical tips of glial-like cells in mouse taste buds. J. Comp. Neurol. 517(1), 1–14 (2009).
  Medline CASGoogle Scholar
• 18 Foster DB, Ho AS, Rucker J et al. Mitochondrial ROMK channel is a molecular component of mitoK(ATP). Circ. Res. 111(4), 446–454 (2012).
  Medline CASGoogle Scholar
• 19 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74(5), 1124–1136 (1986).
  Medline CASGoogle Scholar
• 20 Henn MC, Janjua MB, Kanter EM et al. Adenosine triphosphate-sensitive potassium channel Kir subunits implicated in cardioprotection by diazoxide. J. Am. Heart Assoc. 4(8), e002016 (2015).
  MedlineGoogle Scholar
• 21 Foster MN, Coetzee WA. KATP channels in the cardiovascular system. Physiol. Rev. 96(1), 177–252 (2016).
  Medline CASGoogle Scholar
• 22 Garlid KD, Halestrap AP. The mitochondrial K(ATP) channel: fact or fiction? J. Mol. Cell. Cardiol. 52(3), 578–583 (2012).
  Medline CASGoogle Scholar
• 23 Garcia ML, Priest BT, Alonso-Galicia M et al. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. J. Pharmacol. Exp. Ther. 348(1), 153–164 (2014).
  MedlineGoogle Scholar
• 24 Kharade SV, Flores D, Lindsley CW, Satlin LM, Denton JS. ROMK inhibitor actions in the nephron probed with diuretics. Am. J. Physiol. Renal Physiol. 310(8), F732–F737 (2016).
  Medline CASGoogle Scholar
• 25 Tang H, Zhu Y, Teumelsan N et al. Discovery of MK-7145, an oral small molecule ROMK inhibitor for the treatment of hypertension and heart failure. ACS Med. Chem. Lett. 7(7), 697–701 (2016).
  Medline CASGoogle Scholar
• 26 Hampton C, Zhou X, Priest BT et al. The renal outer medullary potassium channel inhibitor, MK-7145, lowers blood pressure and manifests features of Bartter's syndrome type II phenotype. J. Pharmacol. Exp. Ther. 359(1), 194–206 (2016). •• Preclinical pharmacology of MK-7145, the first Kir1.1 inhibitor to enter clinical development.
  Medline CASGoogle Scholar
• 27 Simon DB, Karet FE, Rodriguez-Soriano J et al. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K⁺ channel, ROMK. Nat. Genet. 14(2), 152–156 (1996).
  Medline CASGoogle Scholar
• 28 Ji W, Foo JN, O'roak BJ et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat. Genet. 40(5), 592–599 (2008). •• Study of heterozygous carriers of KCNJ1 loss-of-function mutations.
  Medline CASGoogle Scholar
• 29 Lu M, Wang T, Yan Q et al. Absence of small conductance K⁺ channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter's) knockout mice. J. Biol. Chem. 277(40), 37881–37887 (2002).
  Medline CASGoogle Scholar
• 30 Lorenz JN, Baird NR, Judd LM et al. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome. J. Biol. Chem. 277(40), 37871–37880 (2002).
  Medline CASGoogle Scholar
• 31 Yan Q, Yang X, Cantone A, Giebisch G, Hebert S, Wang T. Female ROMK null mice manifest more severe Bartter II phenotype on renal function and higher PGE2 production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295(3), R997–R1004 (2008).
  Medline CASGoogle Scholar
• 32 Beesley AH, Ortega B, White SJ. Splicing of a retained intron within ROMK K⁺ channel RNA generates a novel set of isoforms in rat kidney. Am. J. Physiol. 276(3 Pt 1), C585–C592 (1999).
  Medline CASGoogle Scholar
• 33 Dong K, Yan Q, Lu M et al. Romk1 knockout mice do not produce Bartter phenotype but exhibit impaired K excretion. J. Biol. Chem. 291(10), 5259–5269 (2016).
  Medline CASGoogle Scholar
• 34 Zhou X, Zhang Z, Shin MK et al. Heterozygous disruption of renal outer medullary potassium channel in rats is associated with reduced blood pressure. Hypertension 62(2), 288–294 (2013).
  Medline CASGoogle Scholar
• 35 Martelli A, Testai L, Breschi MC, Calderone V. Inhibitors of the renal outer medullary potassium channel: a patent review. Expert Opin. Ther. Pat. 25(9), 1035–1051 (2015).
  Medline CASGoogle Scholar
• 36 Jin W, Lu Z. A novel high-affinity inhibitor for inward-rectifier K⁺ channels. Biochemistry 37(38), 13291–13299 (1998).
  Medline CASGoogle Scholar
• 37 Kanjhan R, Coulson EJ, Adams DJ, Bellingham MC. Tertiapin-Q blocks recombinant and native large conductance K⁺ channels in a use-dependent manner. J. Pharmacol. Exp. Ther. 314(3), 1353–1361 (2005).
  Medline CASGoogle Scholar
• 38 Lewis LM, Bhave G, Chauder BA et al. High-throughput screening reveals a small-molecule inhibitor of the renal outer medullary potassium channel and Kir7.1. Mol. Pharmacol. 76(5), 1094–1103 (2009).
  Medline CASGoogle Scholar
• 39 Bhave G, Chauder BA, Liu W et al. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol. Pharmacol. 79(1), 42–50 (2011).
  Medline CASGoogle Scholar
• 40 Swale DR, Sheehan JH, Banerjee S et al. Computational and functional analyses of a small-molecule binding site in ROMK. Biophys. J. 108(5), 1094–1103 (2015).
  Medline CASGoogle Scholar
• 41 Kharade SV, Flores D, Lindsley CW, Satlin LM, Denton JS. ROMK inhibitor actions in the nephron probed with diuretics. Am. J. Physiol. Renal Physiol. 310(8), F732–F737 (2015).
  MedlineGoogle Scholar
• 42 Ellison DH. Diuretic resistance: physiology and therapeutics. Semin. Nephrol. 19(6), 581–597 (1999).
  Medline CASGoogle Scholar
• 43 Tang H, Walsh SP, Yan Y et al. Discovery of selective small molecule ROMK inhibitors as potential new mechanism diuretics. ACS Med. Chem. Lett. 3(5), 367–372 (2012).
  Medline CASGoogle Scholar
• 44 Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function and physiological roles. Physiol. Rev. 90(1), 291–366 (2010).
  Medline CASGoogle Scholar
• 45 Preisig-Muller R, Schlichthorl G, Goerge T et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc. Natl Acad. Sci. USA 99(11), 7774–7779 (2002).
  Medline CASGoogle Scholar
• 46 Purohit V, Basu AK. Mutagenicity of nitroaromatic compounds. Chem. Res. Toxicol. 13(8), 673–692 (2000).
  Medline CASGoogle Scholar
• 47 Walsh SP, Shahripour A, Tang H et al. Discovery of a potent and selective ROMK inhibitor with pharmacokinetic properties suitable for preclinical evaluation. ACS Med. Chem. Lett. 6(7), 747–752 (2015).
  Medline CASGoogle Scholar
• 48 Zhou X, Forrest MJ, Sharif-Rodriguez W et al. Chronic inhibition of renal outer medullary potassium channel not only prevented but also reversed development of hypertension and end-organ damage in Dahl salt-sensitive rats. Hypertension 69(2), 332–338 (2017).
  Medline CASGoogle Scholar
• 49 Chobanian HR, Guo Y, Pio B et al. The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics. Bioorg. Med. Chem. Lett. 27(4), 1109–1114 (2017).
  Medline CASGoogle Scholar
• 50 Tang H, De Jesus RK, Walsh SP et al. Discovery of a novel subclass of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran- 1(3H)-one. Bioorg. Med. Chem. Lett. 23(21), 5829–5832 (2013).
  Medline CASGoogle Scholar
• 51 Walsh SP, Shahripour A, Tang H et al. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation. Bioorg. Med. Chem. Lett. 26(9), 2339–2343 (2016).
  Medline CASGoogle Scholar
• 52 Zhu Y, De Jesus RK, Tang H et al. Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold. Bioorg. Med. Chem. Lett. 26(23), 5695–5702 (2016).
  Medline CASGoogle Scholar
• 53 Araujo M, Welch WJ, Zhou X et al. Inhibition of ROMK blocks macula densa tubuloglomerular feedback yet causes renal vasoconstriction in anesthetized rats. Am. J. Physiol. Renal Physiol. 310(8), F732–F737 (2017).
  Google Scholar
• 54 Palazzuoli A, Ruocco G, Ronco C, Mccullough PA. Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. Crit. Care 19, 296 (2015).
  MedlineGoogle Scholar
• 55 Wang H, Yang B, Zhang L, Xu D, Wang Z. Direct block of inward rectifier potassium channels by nicotine. Toxicol. Appl. Pharmacol. 164(1), 97–101 (2000).
  Medline CASGoogle Scholar